← Back to Search

Angiotensin II Receptor Blocker

Candesartan for High Blood Pressure in Obesity (END-RF Trial)

Phase < 1
Waitlist Available
Led By Ryan Harris, PHD, CES
Research Sponsored by Augusta University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult between the ages of 18-40 years old
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-treatment baseline and 7 days post-treatment
Awards & highlights

END-RF Trial Summary

This trial will explore how obesity affects blood pressure levels and if high blood pressure in obesity is due to a dysfunction of the ETB receptor.

Who is the study for?
This trial is for adults aged 18-40 who are dealing with high blood pressure and obesity. It's not open to those with cardiovascular, lung, kidney, liver, brain diseases or metabolic disorders; pregnant individuals; people on meds that affect blood vessels or anticoagulants like aspirin; those with anemia, postmenopausal women, or uncontrolled hypertension.Check my eligibility
What is being tested?
The study is testing the effects of Candesartan (a drug) against a placebo to see if it can improve how well ETB receptors work in obese individuals. This could help understand if these receptors play a role in developing high blood pressure due to obesity.See study design
What are the potential side effects?
Candesartan may cause dizziness, increased potassium levels which can affect heart rhythm, low blood pressure especially after standing up quickly, and possible kidney problems. Placebos typically have no active ingredients but can lead to perceived side effects.

END-RF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 40 years old.

END-RF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-treatment baseline and 7 days post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-treatment baseline and 7 days post-treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage Change in Flow-Mediated Dilation (FMD)

Side effects data

From 2008 Phase 4 trial • 315 Patients • NCT00348686
7%
Headache
5%
Dizziness
100%
80%
60%
40%
20%
0%
Study treatment Arm
Candesartan

END-RF Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CandesartanExperimental Treatment1 Intervention
Sub chronic (7 days) Candesartan (16 mg/day)
Group II: PlaceboPlacebo Group1 Intervention
Endothelial function will be determined following a seven day treatment of placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Candesartan
2005
Completed Phase 4
~11970

Find a Location

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,847 Previous Clinical Trials
47,818,211 Total Patients Enrolled
Augusta UniversityLead Sponsor
211 Previous Clinical Trials
85,043 Total Patients Enrolled
Ryan Harris, PHD, CES4.7122 ReviewsPrincipal Investigator - Augusta University
Medical School - University of Kansas, Kansas City, Doctor of Medicine
Augusta University, Medical College of Georgia, Residency in Otolaryngology and Head and Neck Surgery
5Patient Review
The Dr. and his staff were very friendly and efficient. I would highly recommend them to anyone looking for great dental care.

Media Library

Candesartan (Angiotensin II Receptor Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT03583866 — Phase < 1
High Blood Pressure Research Study Groups: Candesartan, Placebo
High Blood Pressure Clinical Trial 2023: Candesartan Highlights & Side Effects. Trial Name: NCT03583866 — Phase < 1
Candesartan (Angiotensin II Receptor Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03583866 — Phase < 1
~5 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top